OMERS ADMINISTRATION Corp Has $2.28 Million Holdings in Quest Diagnostics Incorporated $DGX

OMERS ADMINISTRATION Corp raised its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 642.8% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 11,640 shares of the medical research company’s stock after purchasing an additional 10,073 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Quest Diagnostics were worth $2,281,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Key Financial Inc lifted its stake in Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter worth $25,000. JFS Wealth Advisors LLC grew its stake in shares of Quest Diagnostics by 114.3% in the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after acquiring an additional 80 shares in the last quarter. DV Equities LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at about $27,000. Finally, Sittner & Nelson LLC bought a new position in shares of Quest Diagnostics during the fourth quarter valued at about $29,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Price Performance

Quest Diagnostics stock opened at $235.26 on Wednesday. Quest Diagnostics Incorporated has a 52 week low of $166.75 and a 52 week high of $240.13. The business has a 50-day simple moving average of $204.96 and a 200 day simple moving average of $198.52. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The stock has a market cap of $25.97 billion, a price-to-earnings ratio of 24.97, a PEG ratio of 2.13 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, research analysts forecast that Quest Diagnostics Incorporated will post 11.16 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were given a dividend of $0.86 per share. The ex-dividend date was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

Insider Activity

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. The trade was a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.88% of the company’s stock.

Analyst Ratings Changes

DGX has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Mizuho increased their price target on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Truist Financial boosted their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, Quest Diagnostics currently has an average rating of “Hold” and a consensus price target of $233.25.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.